The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
"Severe neutropenia occurs in a small percentage of patients taking clozapine; however, neutropenia is associated with an ...
Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...
Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...
AbbVie (ABBV) shares dropped 11% premarket as late-stage trials for schizophrenia drug emraclidine did not meet primary ...
On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...
2don MSNOpinion
The FDA’s REMS program has been found to have unintentionally created barriers to accessing clozapine, a crucial ...
An unnecessary FDA policy is making it nearly impossible for schizophrenics without stable medical care to get clozapine, the only medicine useful for treatment-resistant schizophrenia. In the absence ...
The FDA approved clozapine, which is classified as an “atypical” antipsychotic drug, for treatment-resistant schizophrenia in 1990. In 2002, the FDA announced clozapine was effective in reducing the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback